{"id":2486,"date":"2022-10-04T13:21:49","date_gmt":"2022-10-04T13:21:49","guid":{"rendered":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/?page_id=2486"},"modified":"2026-01-29T16:12:41","modified_gmt":"2026-01-29T16:12:41","slug":"publications","status":"publish","type":"page","link":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; custom_padding_last_edited=&#8221;on|phone&#8221; _builder_version=&#8221;4.16&#8243; background_color=&#8221;#f2faff&#8221; background_image=&#8221;https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2018\/12\/Trevi_Banner_A.jpg&#8221; background_position=&#8221;top_center&#8221; custom_padding=&#8221;50px|0px|50px|0px|true|false&#8221; custom_padding_tablet=&#8221;20px||20px||true|false&#8221; custom_padding_phone=&#8221;&#8221; da_disable_devices=&#8221;off|off|off&#8221; global_colors_info=&#8221;{}&#8221; da_is_popup=&#8221;off&#8221; da_exit_intent=&#8221;off&#8221; da_has_close=&#8221;on&#8221; da_alt_close=&#8221;off&#8221; da_dark_close=&#8221;off&#8221; da_not_modal=&#8221;on&#8221; da_is_singular=&#8221;off&#8221; da_with_loader=&#8221;off&#8221; da_has_shadow=&#8221;on&#8221;][et_pb_row custom_padding_last_edited=&#8221;on|phone&#8221; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;36px|0px|36px|0px|false|false&#8221; custom_padding_tablet=&#8221;&#8221; custom_padding_phone=&#8221;0px||0px||true|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; custom_padding_last_edited=&#8221;on|tablet&#8221; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;30px||30px||true|false&#8221; custom_padding_tablet=&#8221;30px||30px||true|false&#8221; custom_padding_phone=&#8221;30px||30px||true|false&#8221; da_disable_devices=&#8221;off|off|off&#8221; box_shadow_style=&#8221;preset1&#8243; saved_tabs=&#8221;all&#8221; global_colors_info=&#8221;{}&#8221; da_is_popup=&#8221;off&#8221; da_exit_intent=&#8221;off&#8221; da_has_close=&#8221;on&#8221; da_alt_close=&#8221;off&#8221; da_dark_close=&#8221;off&#8221; da_not_modal=&#8221;on&#8221; da_is_singular=&#8221;off&#8221; da_with_loader=&#8221;off&#8221; da_has_shadow=&#8221;on&#8221;][et_pb_row column_structure=&#8221;2_3,1_3&#8243; make_equal=&#8221;on&#8221; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;2_3&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|20px||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.16&#8243; header_text_color=&#8221;#00436A&#8221; header_font_size=&#8221;35px&#8221; header_line_height=&#8221;1.3em&#8221; header_2_font=&#8221;|300|||||||&#8221; header_2_text_color=&#8221;#00436a&#8221; header_2_font_size=&#8221;30px&#8221; header_2_line_height=&#8221;1.3em&#8221; custom_margin=&#8221;0px||&#8221; custom_padding=&#8221;0px||20px&#8221; header_font_size_tablet=&#8221;&#8221; header_font_size_phone=&#8221;30px&#8221; header_font_size_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1 style=\"text-align: left;\"><span class=\"et_pb_fullwidth_header_subhead et-fb-editable-element et-fb-editable-element__editing\" contenteditable=\"true\" data-shortcode-id=\"0.0-1540284059056\" data-quickaccess-id=\"subhead\"><strong>Posters &amp; Publications<\/strong><\/span><\/h1>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.5&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; hover_enabled=&#8221;0&#8243; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/jamanetwork.com\/journals\/jama\/article-abstract\/2844186\" target=\"_blank\" rel=\"noopener noreferrer\">Oral Nalbuphine in Idiopathic Pulmonary Fibrosis\u2013Associated Cough: The CORAL Randomized Clinical Trial<\/a><\/span><\/h4>\n<p>Molyneaux P et al., <em>JAMA (2026)<\/em>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.4&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2025\/12\/Kulkarni-et-al.-Understanding-the-Burden-of-Chronic-Cough-in-Patients-with-ILD.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Understanding the Burden of Chronic Cough in Patients with Interstitial Lung Disease: Insights from a U.S. Patient Perspective Survey<\/a><\/span><\/h4>\n<p>Kulkarni et al., <em>poster presentation at PFF Summit (2025)<\/em>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.4&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2025\/10\/Molyneaux-CHEST-2025-Presentation.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">A Randomized, Placebo-Controlled, Parallel-Group Phase 2b Study of Nalbuphine ER for Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis<\/a><\/span><\/h4>\n<p>Molyneaux et al., <em>presentation at CHEST Annual Meeting (2025)<\/em>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.4&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2025\/10\/Satia-et-al.-_CHEST2025_RIVER-PRO.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Patient-Reported Outcomes From a Phase 2a Trial of Extended-Release Nalbuphine for Patients With Refractory Chronic Cough<\/a><\/span><\/h4>\n<p>Satia et al., <em>poster presentation at CHEST Annual Meeting (2025)<\/em>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.4&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2025\/09\/Smith-et-al.-ERS-Congress-2025-RIVER-Primary.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Efficacy and Safety of Nalbuphine Extended-Release in Refractory Chronic Cough: Primary Results From the Phase 2a RIVER Trial<\/a><\/span><\/h4>\n<p>Smith et al., <em>poster presentation at the European Respiratory Society (ERS) Congress (2025)<\/em>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.4&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2025\/09\/Smith-et-al.-ERS-Congress-2025-RIVER-Responder-Analysis.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Responder Analysis of Nalbuphine Extended-Release in Refractory Chronic Cough: Results From the RIVER Phase 2a Trial<\/a><\/span><\/h4>\n<p>Smith et al., <em>poster presentation at the European Respiratory Society (ERS) Congress (2025)<\/em>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.4&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2025\/06\/150208130_CPDD2025_Assessment-of-Human-Abuse-Potential_L2a.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Assessment of Human Abuse Potential of Nalbuphine in Nondependent Recreational Drug Users<\/a><\/span><\/h4>\n<p>Sciascia et al., <em>presentation at CPDD 87th Annual Scientific Meeting (2025)<\/em>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2024\/10\/CHEST-ILD-Abstract-Potpourri-Morice.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Analysis of Relief-of-Cough in Patients With Idiopathic Pulmonary Fibrosis Treated With Oral Nalbuphine Extended Release<\/a><\/span><\/h4>\n<p>Morice et al., <em>presentation at CHEST (2024)<\/em>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2024\/09\/150206721_ERS2024_FINAL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Change in Objective Cough Count Correlates With Improvement in<br \/>Patient-Reported Outcomes of Cough in Patients With Idiopathic Pulmonary Fibrosis<\/a><\/span><\/h4>\n<p>Smith et al., <em>poster presentation at the European Respiratory Society (ERS) Congress (2024)<\/em><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.26.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2024\/07\/Maher-et-al_LondonCough2024_CORAL_L2b.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Sample Size Re-Estimation in an Ongoing Dose-Ranging Study of Nalbuphine Extended-Release for Cough in Idiopathic Pulmonary Fibrosis: The CORAL Study<\/a><\/span><\/h4>\n<p>Maher et al., <em>poster presentation at the 13th International Symposium on Cough (2024).<\/em>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.26.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2024\/07\/Smith-et-al_LondonCough2024_RIVER_L2a.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Refractory Chronic Cough: A Phase 2 Trial in Progress<\/a><\/span><\/h4>\n<p>Smith et al., <em>poster presentation at the 13th International Symposium on Cough (2024).<\/em>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/www.mdpi.com\/2218-1989\/14\/9\/471\" target=\"_blank\" rel=\"noopener noreferrer\">Disposition of Oral Nalbuphine and Its Metabolites in Healthy Subjects and Subjects with Hepatic Impairment: Preliminary Modeling Results Using a Continuous Intestinal Absorption Model with Enterohepatic Recirculation<\/a><\/span><\/h4>\n<p>Nagar, S. et al., <em>Metabolites<\/em> (2024). https:\/\/doi.org\/10.3390\/metabo14090471<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.molpharmaceut.4c00424?ref=pdf#\" target=\"_blank\" rel=\"noopener noreferrer\">A Continuous Intestinal Absorption Model to Predict Drug Enterohepatic Recirculation in Healthy Humans: Nalbuphine as a Model Substrate<\/a><\/span><\/h4>\n<p>Korzekwa K. et al., <em>Molecular Pharmaceutics<\/em> (2024).<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.25.1&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09546634.2024.2355976\" target=\"_blank\" rel=\"noopener noreferrer\">Association of pruritus and chronic cough: an all of us database study<\/a><\/span><\/h4>\n<p>Sharma et al., <em>Journal of Dermatological Treatment (2024).<\/em><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.25.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2024\/05\/Smith.J.ATS2024_FINAL.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Nalbuphine Oral Extended-Release Tablets Reduce Cough Bouts in Patients With Idiopathic Pulmonary Fibrosis<\/a><\/span><\/h4>\n<p>Smith et al., <em>poster presentation at the American Thoracic Society (ATS) 2024 International Conference.<\/em><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.25.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2024\/05\/ATS-2023-Presentation-Maher-et-al-Efficacy-of-Oral-Nalbuphine-Extended-Release-in-Patients-With-Idiopathic-Pulmonary-Fibrosis-Related.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Efficacy of Oral Nalbuphine Extended Release in Patients With Idiopathic Pulmonary Fibrosis Related Chronic Cough: a Phase 2 Study<\/a><\/span><\/h4>\n<p>Maher et al., <em>as presented orally at the American Thoracic Society (ATS) 2023 International Conference.<\/em><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2024\/08\/Maher-et-al_Nalbuphine-extended-release-treatment_ACC-2023.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Nalbuphine extended release treatment achieved rapid and sustained reduction in reported cough frequency in patients with idiopathic pulmonary fibrosis <\/a><\/span><\/h4>\n<p>Maher et al., <em>as presented orally at the American Cough Conference (ACC) 2023.<\/em><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/evidence.nejm.org\/doi\/full\/10.1056\/EVIDoa2300083\" target=\"_blank\" rel=\"noopener noreferrer\">Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis<\/a><\/span><\/h4>\n<p>Maher TM et al.,\u00a0<em>NEJM Evidence<\/em> (2023).<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.25.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2024\/05\/ERS-2023-Wijsenbeek-et-al-Utility-of-EXACT.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Utility of EXACT, a patient-reported outcome instrument, for idiopathic pulmonary fibrosis-related cough<\/a><\/span><\/h4>\n<p>Wijsenbeek et al., <em>poster presentation at the 2023 European Respiratory Society (ERS) International Congress.<\/em><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.25.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2024\/05\/ATS-2023-Maher-et-al-The-Effect-of-Oral-Nalbuphine-Extended-Release-on-Patient-Reported-Outcome-Measures.pdf\" _blank=\"\" rel=\"noopener noreferrer\" target=\"_blank\">The Effect of Oral Nalbuphine Extended Release on Patient-Reported Outcome Measures in Patients With Idiopathic-Pulmonary-Fibrosis-Related Chronic Cough<\/a><\/span><\/h4>\n<p>Maher et al., <em>poster presentation at the American Thoracic Society (ATS) 2023 International Conference.<\/em><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.25.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2024\/05\/ATS-2023-Maher-et-al-Efficacy-of-Oral-Nalbuphine-Extended-Release-in-Patients-With-Idiopathic-Pulmonary-Fibrosis-Related.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Efficacy of Oral Nalbuphine Extended Release in Patients With Idiopathic Pulmonary Fibrosis Related Chronic Cough: a Phase 2 Study<\/a><\/span><\/h4>\n<p>Maher et al., <em>poster presentation at the American Thoracic Society (ATS) 2023 International Conference.<\/em><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdfdirect\/10.1111\/bcp.15663\" target=\"_blank\" rel=\"noopener noreferrer\">A population pharmacokinetic\u2013pharmacodynamic model evaluating efficacy of nalbuphine extended-release in patients with prurigo nodularis<\/a><\/span><\/h4>\n<p>Eudy\u2010Byrne R. et al., <em>British Journal of Clinical Pharmacology<\/em> 89.7 (2023): 2088-2101.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.25.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2024\/05\/BTS-2022-Molyneaux-et-al-Efficacy-of-oral-nalbuphine-extended-release-for-the-treatment-of-chronic-cough-.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Efficacy of oral nalbuphine extended release for the treatment of chronic cough in idiopathic pulmonary fibrosis: data analysis of a phase 2 study<\/a><\/span><\/h4>\n<p>Molyneaux et al.,<em> as presented orally at the British Thoracic Society (BTS) Winter Meeting 2022.<\/em><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.25.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2024\/05\/ICLAF-2022-Maher-et-al-An-interim-analysis-of-a-phase-2-trial-evaluating-oral-nalbuphine-ER.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">An interim analysis of a phase 2 trial evaluating oral nalbuphine extended release for treating chronic cough in idiopathic pulmonary fibrosis<\/a><\/span><\/h4>\n<p>Maher et al., <em>poster presentation at the 21st International Colloquium on Lung and Airway Fibrosis (ICLAF) 2022.<\/em><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.25.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2024\/05\/ERS-2022-Maher-et-al-An-interim-analysis-of-a-phase-2-trial.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">An interim analysis of a phase 2 trial evaluating oral nalbuphine extended release for treating chronic cough in idiopathic pulmonary fibrosis<\/a><\/span><\/h4>\n<p>Maher et al.,<em> as presented orally at the 2022 European Respiratory Society (ERS) International Congress.<\/em><\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36054458\/\" target=\"_blank\" rel=\"noopener noreferrer\">The Role of Kappa-Opioid and Mu-Opioid Receptors in Pruritus: Peripheral and Central Itch Circuits<\/a><\/span><\/h4>\n<p>Kim BS et al.,\u00a0<em>Exp Dermatol.<\/em> (2022).<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666328722000360\" target=\"_blank\" rel=\"noopener noreferrer\">Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: A review of basic science and clinical implications<\/a><\/span><\/h4>\n<p>Elmariah et al.,\u00a0<em>Journal of the American Academy of Dermatology (JAAD) International<\/em> (2021).<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/jdv.17816\" target=\"_blank\" rel=\"noopener noreferrer\">Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase<\/a><\/span><\/h4>\n<p>Weisshaar E. et al.,\u00a0<em>Journal of The European Academy of Dermatology and Venereology<\/em> (2021).<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34192369\/\" target=\"_blank\" rel=\"noopener noreferrer\">Prevalence, Incidence, and Presence of Comorbidities in Patients with Prurigo and Pruritus in Germany: A Population-Based Claims Data Analysis<\/a><\/span><\/h4>\n<p>Augustin et al.,\u00a0<em>Journal of The European Academy of Dermatology and Venereology<\/em> (2021).<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.25.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2023\/11\/ESDR-21-Liver-Impairment_Poster_Final_09-17-21.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Safety and Pharmacokinetics of Nalbuphine Following Administration of Nalbuphine ER Tablets in Subjects With Impaired Hepatic Function<\/a><\/span><\/h4>\n<p>Rohatagi S. et al., p<em>oster presentation at European Society for Dermatological Research (ESDR) 50th Annual Meeting<\/em> (2021).<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2021\/04\/MDD21-Poster_Trevi-Therapeutics_Kim_12-23-20_FINAL.pdf\" _blank=\"\" rel=\"noopener noreferrer\" target=\"_blank\">The Role of Kappa- and Mu- Opioid Receptors in Pruritus <\/a><\/span><\/h4>\n<p>Kim B et al., as presented at Maui Derm for Dermatologists 2021.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2021\/04\/MDD21-Poster_Trevi-Therapeutics_Elmariah_12-23-20_FINAL.pdf\" _blank=\"\" rel=\"noopener noreferrer\" target=\"_blank\">Modulation of the Mu and Kappa Opioid Axis for Treatment of Chronic Pruritus<\/a><\/span><\/h4>\n<p>Elmariah et al., as presented at Maui Derm for Dermatologists 2021.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/www.jaadinternational.org\/article\/S2666-3287(20)30067-5\/fulltext\" target=\"_blank\" rel=\"noopener noreferrer\">Prevalence of prurigo nodularis in the United States of America: A retrospective database analysis<\/a><\/span><\/h4>\n<p>St\u00e4nder et al.,\u00a0<em>The American Academy of Dermatology (JAAD) International<\/em> (2020).<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2021\/04\/FC20-Poster-Trevi-Therapeutics-Mathur.pdf\" _blank=\"\" rel=\"noopener noreferrer\" target=\"_blank\">A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus<\/a><\/span><\/h4>\n<p>Mathur V. and Sciascia T., as presented at the 2020 Fall Clinical Dermatology Conference.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2021\/04\/FC20-Poster-Trevi-Therapeutics-Weisshaar.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Efficacy and Safety of Oral Nalbuphine Extended Release in Prurigo Nodularis: Results of a Phase 2, Randomized, Controlled Trial with an Open-Label Extension Phase<\/a><\/span><\/h4>\n<p>Weisshaar et al., as presented at the 2020 Fall Clinical Dermatology Conference.<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/www.medicaljournals.se\/acta\/content\/html\/10.2340\/00015555-3518\" target=\"_blank\" rel=\"noopener noreferrer\">Prevalence of Prurigo Nodularis in Poland<\/a><\/span><\/h4>\n<p>Reich and Ryczek,\u00a0<em>Acta Dermato Venereologica<\/em> (2020).<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2021\/04\/AAD-2020-Poster-Stander-et-al..pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Prevalence of Prurigo Nodularis in the United States: Findings of a Retrospective Database Analysis<\/a><\/span><\/h4>\n<p> St\u00e4nder et al., as presented at the 2020 AAD Annual Meeting.[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; link_font=&#8221;||||||||&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><span style=\"color: #7db2ce;\"><a style=\"color: #7db2ce;\" href=\"https:\/\/eprintservices.trustrack.com\/weblink\/d7f5762d685ba7e301685c6cfeda0097\" target=\"_blank\" rel=\"noopener noreferrer\">A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of\u00a0Nalbuphine\u00a0ER Tablets for Uremic\u00a0Pruritus<\/a><\/span><\/h4>\n<p>Mathur et al., <em>American Journal of Nephrology<\/em> (2017)<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; link_font=&#8221;||||||||&#8221; link_text_color=&#8221;#7db2ce&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><a href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2019\/01\/NKF_Poster_SevereSubsetTR02_4-5-16_uploadedtoNKF.pdf\" target=\"blank\" rel=\"attachment wp-att-864 noopener\">Nalbuphine ER Tablets in Hemodialysis Patients with Severe Uremic Pruritus: Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial<\/a><\/h4>\n<p>Kumar et al., as presented at the National Kidney Foundation Spring 2016 Meeting.[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; link_font=&#8221;||||||||&#8221; link_text_color=&#8221;#7db2ce&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><a href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2019\/01\/NKF_Poster_TR02ext_uploaded_to_NKF.pdf\" target=\"blank\" rel=\"attachment wp-att-861 noopener\">Long-Term Effects of Nalbuphine ER Tablets in Hemodialysis Patients with Uremic Pruritus: A Multicenter Open-Label Trial<\/a><\/h4>\n<p>Kumar et al., as presented at the National Kidney Foundation Spring 2016 Meeting.[\/et_pb_text][et_pb_text _builder_version=&#8221;4.26.0&#8243; link_font=&#8221;||||||||&#8221; link_text_color=&#8221;#7db2ce&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><a href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2024\/07\/Nalubuphine-MetID-AAPS-2015-Poster.pdf\" target=\"blank\" rel=\"attachment wp-att-867 noopener\">Isolation, Characterization, and Synthesis of N-(4-Hydroxy-3-Methylene-Butanoic Acid) Nornalbuphine, a Previously Unidentified Nalbuphine Metabolite<\/a><\/h4>\n<p>Thornquest et al., <em>poster presented at AAPS Annual Meeting <\/em>(2015).<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.16&#8243; link_font=&#8221;||||||||&#8221; link_text_color=&#8221;#7db2ce&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><a href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2019\/01\/TR01_PK_BMC_nephrology_2015.pdf\" target=\"blank\" rel=\"attachment wp-att-867 noopener\">Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus<\/a><\/h4>\n<p>Hawi et al., <em>BMC Nephrology <\/em>(2015).<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; link_font=&#8221;||||||||&#8221; link_text_color=&#8221;#7db2ce&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><a href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2019\/01\/SID_poster_Trevi_Therapeutics_567_v2.pdf\" target=\"blank\" rel=\"attachment wp-att-897 noopener\">Pharmacokinetics of nalbuphine hydrochloride proof-of-concept study with pharmacokinetics demonstrating anti-pruritic activity of oral nalbuphine in hemodialysis patients with uremic pruritus<\/a><\/h4>\n<p>Hawi et al., as presented at the 2014 Meeting of the Society for Investigative Dermatology.[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; link_font=&#8221;||||||||&#8221; link_text_color=&#8221;#7db2ce&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><a href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2019\/01\/ACCP_Poster_1998512_9-8-14_Final_v2.pdf\" target=\"blank\" rel=\"attachment wp-att-901 noopener\">Pharmacokinetics of Nalbuphine Hydrochloride Extended Release Tablets in Hemodialysis and Healthy Subjects following Multiple Escalating Oral Doses<\/a><\/h4>\n<p>Hawi et al., as presented at the 2014 Meeting of the American College of Pharmacology.[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; link_font=&#8221;||||||||&#8221; link_text_color=&#8221;#7db2ce&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><a href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2019\/01\/TRV_Nalbuphine_PSTR_ASN_2014-11-06_v2.pdf\" target=\"blank\" rel=\"attachment wp-att-905 noopener\">Exploring Clinical and Pharmacological Effects of Nalbuphine HCl Oral Tablets in Hemodialysis Subjects with Pruritus<\/a><\/h4>\n<p>Sciascia et al., as presented at\u00a0American Society of Nephrology\u2019s 2014 Kidney Week.[\/et_pb_text][et_pb_text _builder_version=&#8221;4.27.0&#8243; link_font=&#8221;||||||||&#8221; link_text_color=&#8221;#7db2ce&#8221; link_line_height=&#8221;1.3em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;Muli|700|||||||&#8221; header_4_line_height=&#8221;1.4em&#8221; custom_margin=&#8221;20px||-5px&#8221; custom_padding=&#8221;16px||16px&#8221; border_width_top=&#8221;1px&#8221; border_color_top=&#8221;#a5b3ab&#8221; border_style_top=&#8221;dotted&#8221; border_color_bottom=&#8221;#a5b3ab&#8221; border_style_bottom=&#8221;dotted&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h4><a href=\"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-content\/uploads\/2019\/01\/Trevi_Itch-Poster_V3-3_v2.pdf\" target=\"blank\" rel=\"attachment wp-att-906 noopener\">Nalbuphine attenuates itch in the substance\u00a0P-induced mouse model<\/a><\/h4>\n<p>Hawi et al., as presented at\u00a07th World Congress on Itch (2013).[\/et_pb_text][et_pb_button button_url=&#8221;https:\/\/ir.trevitherapeutics.com&#8221; button_text=&#8221;VIEW NEWS&#8221; button_alignment=&#8221;left&#8221; admin_label=&#8221;Texts&#8221; _builder_version=&#8221;4.16&#8243; custom_button=&#8221;on&#8221; button_text_size=&#8221;15px&#8221; button_text_color=&#8221;#9fa615&#8243; button_border_width=&#8221;2px&#8221; button_border_color=&#8221;#9fa615&#8243; button_border_radius=&#8221;0px&#8221; button_letter_spacing=&#8221;3px&#8221; button_font=&#8221;Oswald|||on|&#8221; button_use_icon=&#8221;off&#8221; custom_margin=&#8221;46px|||&#8221; custom_padding=&#8221;||&#8221; button_border_color_hover=&#8221;#c99872&#8243; button_border_radius_hover=&#8221;0px&#8221; button_letter_spacing_hover=&#8221;3px&#8221; button_bg_color_hover=&#8221;#c99872&#8243; global_colors_info=&#8221;{}&#8221; button_text_size__hover_enabled=&#8221;off&#8221; button_one_text_size__hover_enabled=&#8221;off&#8221; button_two_text_size__hover_enabled=&#8221;off&#8221; button_text_color__hover_enabled=&#8221;off&#8221; button_one_text_color__hover_enabled=&#8221;off&#8221; button_two_text_color__hover_enabled=&#8221;off&#8221; button_border_width__hover_enabled=&#8221;off&#8221; button_one_border_width__hover_enabled=&#8221;off&#8221; button_two_border_width__hover_enabled=&#8221;off&#8221; button_border_color__hover_enabled=&#8221;on&#8221; button_border_color__hover=&#8221;#9fa615&#8243; button_one_border_color__hover_enabled=&#8221;off&#8221; button_two_border_color__hover_enabled=&#8221;off&#8221; button_border_radius__hover_enabled=&#8221;on&#8221; button_border_radius__hover=&#8221;0px&#8221; button_one_border_radius__hover_enabled=&#8221;off&#8221; button_two_border_radius__hover_enabled=&#8221;off&#8221; button_letter_spacing__hover_enabled=&#8221;on&#8221; button_letter_spacing__hover=&#8221;3px&#8221; button_one_letter_spacing__hover_enabled=&#8221;off&#8221; button_two_letter_spacing__hover_enabled=&#8221;off&#8221; button_bg_color__hover_enabled=&#8221;on&#8221; button_bg_color__hover=&#8221;rgba(214,216,93,0.31)&#8221; button_one_bg_color__hover_enabled=&#8221;off&#8221; button_two_bg_color__hover_enabled=&#8221;off&#8221;][\/et_pb_button][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||0px&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Posters &amp; PublicationsOral Nalbuphine in Idiopathic Pulmonary Fibrosis\u2013Associated Cough: The CORAL Randomized Clinical Trial Molyneaux P et al., JAMA (2026)Understanding the Burden of Chronic Cough in Patients with Interstitial Lung Disease: Insights from a U.S. Patient Perspective Survey Kulkarni et al., poster presentation at PFF Summit (2025)A Randomized, Placebo-Controlled, Parallel-Group Phase 2b Study of Nalbuphine [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-2486","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-json\/wp\/v2\/pages\/2486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-json\/wp\/v2\/comments?post=2486"}],"version-history":[{"count":54,"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-json\/wp\/v2\/pages\/2486\/revisions"}],"predecessor-version":[{"id":4052,"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-json\/wp\/v2\/pages\/2486\/revisions\/4052"}],"wp:attachment":[{"href":"https:\/\/s2.designcostaging.com\/clients\/trevitherapeutics-staging\/wp-json\/wp\/v2\/media?parent=2486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}